Powder: -20°C for 3 years | In solvent: -80°C for 1 year
HO-3867是一种 STAT3的选择性有效抑制剂,有抗肿瘤活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 328 | 现货 | ||
2 mg | ¥ 458 | 现货 | ||
5 mg | ¥ 663 | 现货 | ||
10 mg | ¥ 1,060 | 现货 | ||
25 mg | ¥ 2,120 | 现货 | ||
50 mg | ¥ 3,390 | 现货 | ||
100 mg | ¥ 5,390 | 现货 | ||
200 mg | ¥ 7,360 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 678 | 现货 |
产品描述 | HO-3867, an analog of curcumin, is a sspecific STAT3 inhibitor. |
激酶实验 | Scintillation Proximity Assay, 125I-FGF-2 Binding: SPA protein A beads are supplied as a suspension in PBS at 20 mg/mL, then diluted with binding buffer (KCl, 400 mg/L; MgSO4 200 mg/L; NaCl 6.4 g/L; NaHCO3 3.7 g/L; NaH2PO4 0.141 mg/mL; bis Tris Propane 11.292 g/L; Glucose 4.5 g/L; Gelatin 0.1 %; pH 7.0) at 10 mg/mL. 125I-FGF-2 radioligand and FGFR-1IIIc? - Fc Chimera are diluted into binding buffer. Binding was performed on 96-well plates coated with 0.1 % gelatin. Total assay volume is 0.1 mL. Binding of 125I-FGF-2 is determined by incubation of SPA beads coated with protein A (0.5 mg/assay) with FGFR-1IIIc? - Fc chimera soluble receptor (5 ng/assay), FGF-2 (20 ng/assay) is used for non-specific binding determinations. |
细胞实验 | Cell viability is determined by a colorimetric assay using MTT. In the mitochondria of living cells, yellow MTT undergoes a reductive conversion to formazan, producing a purple color. Cells, grown to ~80% confluence in 75-mm flasks, are trypsinized, counted, seeded in 96-well plates with an average population of 7,000 cells/well, incubated overnight, and then treated with HO-3867 for 24 h. All experiments are done using 8 replicates and repeated at least three times. (Only for Reference) |
别名 | HO3867 |
分子量 | 464.55 |
分子式 | C28H30F2N2O2 |
CAS No. | 1172133-28-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 6 mg/mL (12.91 mM), warmed
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 11 mg/mL (23.7 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 2.1526 mL | 10.7631 mL | 21.5262 mL | 53.8155 mL |
5 mM | 0.4305 mL | 2.1526 mL | 4.3052 mL | 10.7631 mL | |
10 mM | 0.2153 mL | 1.0763 mL | 2.1526 mL | 5.3816 mL | |
DMSO | 20 mM | 0.1076 mL | 0.5382 mL | 1.0763 mL | 2.6908 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
HO-3867 1172133-28-6 Apoptosis JAK/STAT signaling Stem Cells STAT inhibit Inhibitor HO3867 HO 3867 inhibitor